신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물
    2.
    发明公开
    신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물 有权
    新颖的色谱衍生物,药物接受的盐或其异构体,其制备方法和药物组合物,用于预防或治疗含有作为活性成分的PAR-1相关疾病

    公开(公告)号:KR1020120111886A

    公开(公告)日:2012-10-11

    申请号:KR1020110114754

    申请日:2011-11-04

    Abstract: PURPOSE: A pharmaceutical composition containing novel chromeme derivative, pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat blood clot-related diseases or cancer. CONSTITUTION: A chromene derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the chromene derivative, pharmaceutically acceptable salt, isomer as an active ingredient. A pharmaceutical composition for cardiovascular disease treatment aid contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient. A PAR-1 antagonist contains the chromene derivative, pharmaceutically acceptable salt, or isomer as an active ingredient.

    Abstract translation: 目的:提供含有新的chromeme衍生物,其药学上可接受的盐或异构体的药物组合物,用于预防或治疗血块相关疾病或癌症。 构成:色烯衍生物由化学式1表示。用于预防或治疗PAR-1活化相关疾病的药物组合物含有色烯衍生物,药学上可接受的盐,异构体作为活性成分。 用于心血管疾病治疗助剂的药物组合物含有色烯衍生物,药学上可接受的盐或异构体作为活性成分。 PAR-1拮抗剂含有色烯衍生物,药学上可接受的盐或异构体作为活性成分。

    신규한 피리딘을 포함하는 알킬로 치환된 인덴 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물
    6.
    发明公开
    신규한 피리딘을 포함하는 알킬로 치환된 인덴 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물 有权
    由含有吡啶,含有药用盐或其异构体的烷基取代的新型衍生物,其制备方法和用于预防或治疗含有作为活性成分的PAR-1相关疾病的药物组合物

    公开(公告)号:KR1020120111887A

    公开(公告)日:2012-10-11

    申请号:KR1020110114755

    申请日:2011-11-04

    Abstract: PURPOSE: A pharmaceutical composition containing an alkyl-substituted indene derivative containing novel pyridine, or pharmaceutically acceptable salts or isomers thereof is provided to prevent or treat PAR-1 related diseases, inflammation, or cancer. CONSTITUTION: An alkyl-substituted indene derivative containing pyridine is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating PAR-1 activation-related diseases contains the indene derivative, salts, or isomers as an active ingredient. A pharmaceutical composition for cardiovascular treatment aid is alternately used with cardiovascular drugs such as aspirin, clopidogrel, ticlopidine, abciximab, or tirofiban.

    Abstract translation: 目的:提供含有含有新吡啶的烷基取代茚衍生物或其药学上可接受的盐或异构体的药物组合物,用于预防或治疗PAR-1相关疾病,炎症或癌症。 构成:含有吡啶的烷基取代的茚衍生物由化学式1表示。用于预防或治疗PAR-1活化相关疾病的药物组合物含有茚衍生物,盐或异构体作为活性成分。 用于心血管治疗助剂的药物组合物与心血管药物如阿司匹林,氯吡格雷,噻氯匹定,阿昔单抗或替罗非班交替使用。

    4-아실-5-피라졸릴 4-톨루엔 술포네이트 유도체의 제법
    7.
    发明授权
    4-아실-5-피라졸릴 4-톨루엔 술포네이트 유도체의 제법 失效
    4-乙酰基-5-吡咯烷基4-叔丁基磺酸盐衍生物的制备方法

    公开(公告)号:KR1019900001081B1

    公开(公告)日:1990-02-26

    申请号:KR1019860005355

    申请日:1986-07-02

    Abstract: (a) reacting 1,3- diketo cpds. with hydrazine derivs. in solvnet i.e. C1-6 alcohol, C1-6 alkylcyano cpds. or these mixt. to form 5-pyrazolone derivs.; (b) reacting with metal carbonate and acylhalide to form 4-acryl-5- hydroxypyrazole derivs.; and (c) reacting with 4-toluene sulfonyl chloride. The rxn. carried out in an vessel. Prepg. cpds. are useful as a herbicide.

    Abstract translation: (a)使1,3-二酮Cpds反应。 与肼衍生物。 在溶剂合物中,即C 1-6醇,C 1-6烷基氰基。 或这些混合。 以形成5-吡唑啉酮衍生物。 (b)与金属碳酸盐和酰卤反应形成4-丙烯酰基-5-羟基吡唑衍生物。 和(c)与4-甲苯磺酰氯反应。 rxn。 在船上进行 Prepg。 国家方案文件。 可用作除草剂。

    신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물
    8.
    发明公开
    신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 PAR-1 관련 질환의 예방 또는 치료용 약학적 조성물 无效
    新颖的色谱衍生物,药物接受的盐或其异构体,其制备方法和药物组合物,用于预防或治疗含有作为活性成分的PAR-1相关疾病

    公开(公告)号:KR1020140010465A

    公开(公告)日:2014-01-24

    申请号:KR1020140000817

    申请日:2014-01-03

    Abstract: The present invention relates to novel chromene derivatives as thrombin receptor antagonist, pharmaceutically acceptable salts or isomer thereof, a method for preparing the same, and a pharmaceutical composition for preventing or treating PAR-1 related diseases, containing the same as an active ingredient. The chromene derivatives of the present invention exhibit an excellent PAR-1 antagonistic effect, and thus can be used for a pharmaceutical composition for preventing or treating PAR-1 related diseases and can be used, as an antagonist, in preventing or treating thrombosis-related diseases, inflammation, or cancers, including coronary artery diseases, vein thrombosis, cerebrovascular diseases, cardiovascular diseases such as atherosclerosis, restenosis, blood clots, high blood pressure, arrhythmia, angina, and heart failure, and the like.

    Abstract translation: 本发明涉及新颖的色烯衍生物作为凝血酶受体拮抗剂,其药学上可接受的盐或异构体,其制备方法和用于预防或治疗PAR-1相关疾病的药物组合物,其含有活性成分。 本发明的色烯衍生物显示出优异的PAR-1拮抗作用,因此可用于预防或治疗PAR-1相关疾病的药物组合物,并可用作预防或治疗血栓形成相关的拮抗剂 疾病,炎症或癌症,包括冠状动脉疾病,静脉血栓形成,脑血管疾病,心血管疾病如动脉粥样硬化,再狭窄,血块,高血压,心律失常,心绞痛和心力衰竭等。

    트롬빈 수용체 길항제인 [6+5]접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
    9.
    发明公开
    트롬빈 수용체 길항제인 [6+5]접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 有权
    [6 + 5]作为硫蛋白拮抗剂的熔融双酚A,其制备方法和含有BICYCLES的药物组合物

    公开(公告)号:KR1020120000528A

    公开(公告)日:2012-01-02

    申请号:KR1020110061373

    申请日:2011-06-23

    Abstract: PURPOSE: A novel [6+5]fused bicycle derivative and a pharmaceutical composition containing the same are provided to be used as a therapeutic agent for treating platelet aggregation, arteriosclerosis, vascular restenosis, blood clotting, and hypertension. CONSTITUTION: A novel [6+5]fused bicycle derivative is denoted by chemical formula 1. A method for preparing the composition of chemical formula 1 comprises a step of reacting compounds of chemical formulas 2 and 3 or reacting compounds of chemical formulas 4 and 5. A PAR-1 antagonist composition contains the compound of chemical formula 1, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable carrier.

    Abstract translation: 目的:提供一种新型[6 + 5]融合自行车衍生物和含有它的药物组合物,用作治疗血小板聚集,动脉硬化,血管再狭窄,凝血和高血压的治疗剂。 组成:化学式1表示新的[6 + 5]稠合自行车衍生物。化学式1的组合物的制备方法包括使化学式2和3的化合物或化学式4和5的化合物反应的步骤 PAR-1拮抗剂组合物含有化学式1的化合物,其药学上可接受的盐或药学上可接受的载体。

Patent Agency Ranking